ResearcherChina Pharmaceutical UniversityNo recent work listed

B. Li

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5070454839. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2022: 1 paper

Papers 1

The inhibitory effect of LINC00261 upregulation on the pancreatic cancer EMT process is mediated by KLF13 via the mTOR signaling pathway. Co-author DOI 10.1007/s12094-021-02747-x ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Shuyang Pang · 1 shared paper, 2022 · strength 0.19
- Paper The inhibitory effect of LINC00261 upregulation on the pancreatic cancer EMT process is mediated by KLF13 via the mTOR … DOI 10.1007/s12094-021-02747-x ↗
Changlin Zhou · 1 shared paper, 2022 · strength 0.19
- Paper The inhibitory effect of LINC00261 upregulation on the pancreatic cancer EMT process is mediated by KLF13 via the mTOR … DOI 10.1007/s12094-021-02747-x ↗
Yu Zhou · 1 shared paper, 2022 · strength 0.19
- Paper The inhibitory effect of LINC00261 upregulation on the pancreatic cancer EMT process is mediated by KLF13 via the mTOR … DOI 10.1007/s12094-021-02747-x ↗
Baiyong Shen · 1 shared paper, 2022 · strength 0.19
- Paper The inhibitory effect of LINC00261 upregulation on the pancreatic cancer EMT process is mediated by KLF13 via the mTOR … DOI 10.1007/s12094-021-02747-x ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.